{"id":"das181-ol","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAS181 consists of the extracellular domain of human ACE2 fused to the Fc region of human IgG1, enabling it to bind to viral spike proteins and prevent viral attachment to host cells. This mechanism allows it to act as a decoy receptor, sequestering virus particles and reducing viral infectivity. The drug is designed to provide broad antiviral activity against multiple respiratory viruses including influenza and coronaviruses.","oneSentence":"DAS181 is a recombinant fusion protein that blocks viral entry by presenting a soluble receptor domain that captures and neutralizes respiratory viruses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:45.088Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory viral infections (influenza, COVID-19, other respiratory viruses)"}]},"trialDetails":[{"nctId":"NCT03808922","phase":"PHASE3","title":"Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","status":"RECRUITING","sponsor":"Ansun Biopharma, Inc.","startDate":"2019-05-23","conditions":"Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised","enrollment":274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DAS181 OL","genericName":"DAS181 OL","companyName":"Ansun Biopharma, Inc.","companyId":"ansun-biopharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAS181 is a recombinant fusion protein that blocks viral entry by presenting a soluble receptor domain that captures and neutralizes respiratory viruses. Used for Respiratory viral infections (influenza, COVID-19, other respiratory viruses).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}